VIB’s antiviral treatment developer has closed its series A round following a $22.6m extension backed by the research institute, V-Bio Ventures and Vives Inter-University Fund.
ExeVir Bio, a Belgium-based antibody therapy spinout of VIB, has closed its series A round at $50m with a $22.6m extension featuring VIB and its V-Bio Ventures affiliate as well as Université catholique de Louvain’s Vives Inter-University Fund.
Venture capital firm Fund+ led the extension, which also featured UCB Ventures, the corporate venturing subsidiary of pharmaceutical firm UCB, as well as SFPI-FPIM, SRIW, Noshaq, SambrInvest and unnamed Belgian family offices.
ExeVir Bio is developing antibody-based therapies to treat and protect against viral infections. Its lead compound, XVR011, is being developed to guard against Sars-CoV-2 – the virus which causes the covid-19 disease – and other coronaviruses.
The company will use the additional capital to advance XVR011 through phase 1b and phase 2 clinical trials.
It had previously received $26.6m in a July 2020 first close led by Fund+, when VIB, V-Bio Ventures, SFPI-FPIM, UCB Ventures and a number of Belgian family offices also took part.
– A version of this article first appeared on our sister site, Global Corporate Venturing.
